Susquehanna Fundamental Investments LLC Buys Shares of 92,387 CRISPR Therapeutics AG (NASDAQ:CRSP)

Susquehanna Fundamental Investments LLC bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 92,387 shares of the company's stock, valued at approximately $3,636,000. Susquehanna Fundamental Investments LLC owned about 0.11% of CRISPR Therapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of CRSP. Highline Wealth Partners LLC acquired a new position in CRISPR Therapeutics in the 4th quarter worth about $39,000. Western Pacific Wealth Management LP raised its holdings in CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after buying an additional 500 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in CRISPR Therapeutics during the 3rd quarter worth approximately $40,000. Spire Wealth Management increased its position in CRISPR Therapeutics by 303.7% in the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company's stock valued at $78,000 after acquiring an additional 1,482 shares during the period. Finally, MCF Advisors LLC bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at $80,000. Institutional investors own 69.20% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CRSP. HC Wainwright reaffirmed a "buy" rating and set a $65.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. TD Cowen raised CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price objective on the stock in a research note on Wednesday, February 12th. Morgan Stanley increased their target price on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an "underweight" rating in a research report on Friday, February 14th. Bank of America dropped their price target on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. Finally, StockNews.com upgraded shares of CRISPR Therapeutics to a "sell" rating in a research report on Friday, March 21st. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $73.11.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 2,850 shares of the company's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the sale, the general counsel now directly owns 77,530 shares of the company's stock, valued at $3,288,822.60. This represents a 3.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Julianne Bruno sold 1,198 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the transaction, the chief operating officer now directly owns 8,263 shares of the company's stock, valued at approximately $350,516.46. This trade represents a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,381 shares of company stock valued at $1,608,243. 4.10% of the stock is owned by insiders.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock traded up $0.52 during trading hours on Friday, reaching $38.25. The company's stock had a trading volume of 1,648,512 shares, compared to its average volume of 1,649,929. The company has a market capitalization of $3.30 billion, a P/E ratio of -8.75 and a beta of 1.88. The stock's fifty day simple moving average is $38.97 and its two-hundred day simple moving average is $43.15. CRISPR Therapeutics AG has a one year low of $30.04 and a one year high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, research analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.